CRISPR Therapeutics AG [NASDAQ: CRSP] traded at a high on 2025-06-19, posting a 2.87 gain after which it closed the day’ session at $44.43.
The results of the trading session contributed to over 5691441 shares changing hands. Over the past one week, the price volatility of CRISPR Therapeutics AG stands at 1.76% while the volatility over the past one month is 2.90%.
The market cap for CRSP stock reached $3.84 billion, with 86.36 million shares outstanding and 82.79 million shares in the current float. Compared to the average trading volume of 2.20M shares, CRSP reached a trading volume of 5691441 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about CRISPR Therapeutics AG [CRSP]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CRSP shares is $77.21 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CRSP stock is a recommendation set at 1.90. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Evercore ISI have made an estimate for CRISPR Therapeutics AG shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on February 14, 2025. The new note on the price target was released on February 12, 2025, representing the official price target for CRISPR Therapeutics AG stock. Previously, the target price had yet another raise to $65, while H.C. Wainwright analysts kept a Buy rating on CRSP stock. On August 06, 2024, analysts decreased their price target for CRSP shares from 88 to 84.
The Average True Range (ATR) for CRISPR Therapeutics AG is set at 2.41, with the Price to Sales ratio for CRSP stock in the period of the last 12 months amounting to 101.86. The Price to Book ratio for the last quarter was 2.10, with the Price to Cash per share for the same quarter was set at 21.52.
How has CRSP stock performed recently?
CRISPR Therapeutics AG [CRSP] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 7.01. With this latest performance, CRSP shares gained by 14.87% in over the last four-week period, additionally plugging by 1.48% over the last 6 months – not to mention a drop of -30.10% in the past year of trading.
CRISPR Therapeutics AG [CRSP]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and CRISPR Therapeutics AG [CRSP] shares currently have an operating margin of -1259.20% and a Gross Margin at -271.64%. CRISPR Therapeutics AG’s Net Margin is presently recorded at -1023.64%.
Return on Equity for this stock declined to -16.75%, with Return on Assets sitting at -16.75%.
Earnings analysis for CRISPR Therapeutics AG [CRSP]
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for CRSP. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for CRISPR Therapeutics AG go to 5.55%.
Insider trade positions for CRISPR Therapeutics AG [CRSP]
The top three institutional holders of CRSP stocks are: CAPITAL INTERNATIONAL INVESTORS with ownership of 7.87 million shares, which is approximately 9.2619%. ARK INVESTMENT MANAGEMENT LLC, holding 7.78 million shares of the stock with an approximate value of $$420.12 million in CRSP stocks shares; and ARK INVESTMENT MANAGEMENT LLC, currently with $$170.21 million in CRSP stock with ownership which is approximately 3.7111%.
